Bharath Wootla

Pathophysiology of catalytic antibodies.

Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G.

Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII.

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.

A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes.

Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice.

Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.

Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.

Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients.

Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies.

Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.

NHE4 is critical for the renal handling of ammonia in rodents.

Tissue kallikrein permits early renal adaptation to potassium load.

Catalytic antibodies and severe sepsis.

Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies.

Proteolytic antibodies activate factor IX in patients with acquired hemophilia.

Autoantibodies with enzymatic properties in human autoimmune diseases.

Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis.

Deletion of beta-2-microglobulin ameliorates spinal cord lesion load and promotes recovery of brainstem NAA levels in a murine model of multiple sclerosis.

Need for a paradigm shift in therapeutic approaches to CNS injury.

Is multiple sclerosis an autoimmune disease?

High-affinity binding of remyelinating natural autoantibodies to myelin-mimicking lipid bilayers revealed by nanohole surface plasmon resonance.

PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor.

The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment.

CD8(+) T cells in multiple sclerosis.

IVIg treatment reduces catalytic antibody titers of renal transplanted patients.

Polyclonal and monoclonal antibodies in clinic.

Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire.

Applications of SPR for the characterization of molecules important in the pathogenesis and treatment of neurodegenerative diseases.

Deletion of Virus-specific T-cells Enhances Remyelination in a Model of Multiple Sclerosis.

Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice.

Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders.

A single dose of a neuron-binding human monoclonal antibody improves brainstem NAA concentrations, a biomarker for density of spinal cord axons, in a model of progressive multiple sclerosis.

Abbreviated exposure to hypoxia is sufficient to induce CNS dysmyelination, modulate spinal motor neuron composition, and impair motor development in neonatal mice.

A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis.

Naturally Occurring Monoclonal Antibodies and Their Therapeutic Potential for Neurologic Diseases.

Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease.

Tryptophan Metabolites and Their Impact on Multiple Sclerosis Progression.

Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression.

Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients.

A monoclonal natural human IgM protects axons in the absence of remyelination.